A lot has happened in 3 years, you cannot really make a direct comparison. The drug was not rejected. The FDA recommended a larger Phase III trial. In 2009, the FDA did not consider CFS a "serious and life threatening disease" and approval for drugs other than serious or life threatening, the FDA almost always required 2 Phase III trials. (The 2009 submission was with 1 phase III and 1 phase II)
And with the new FDASIA law - the rules have changed completely. The FDA now considers CFS a 'serious and life threatening disease" - language straight out of FDASIA.
This article very succinctly outlines what will be presented to the Advisory Committee